Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefixime + clavulanic acid is an oral fixed-dose combination antibiotic consisting of a third-generation cephalosporin and a beta-lactamase inhibitor. Cefixime works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), which leads to cell lysis and death. Clavulanic acid acts as a suicide inhibitor of beta-lactamase enzymes, which are produced by certain bacteria to degrade beta-lactam antibiotics. By neutralizing these enzymes, clavulanic acid prevents the degradation of cefixime, thereby restoring and expanding its spectrum of activity against beta-lactamase-producing organisms. This combination is commonly indicated for the treatment of various bacterial infections, including acute otitis media, respiratory tract infections, and urinary tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefixime + clavulanic acid.